Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 10Breast Neoplasms 5Sarcoma 3Prostatic Neoplasms 3Fallopian Tube Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Recurrence 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Castration Resistant Prostate Cancer 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Female Breast Cancer Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Cancer Metastatic 1Advanced Solid Tumors 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × fluzoparib × Clear all
NCT04535687 2023-06-13

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Completed
1 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡